Is a weight loss pill as effective as an injection?

Quick answer

A pill is not inherently less effective than an injection, but trial averages from different studies cannot establish a direct comparison. Foundayo's reported trial result applies to a particular study population, dose, and timeframe, not a guaranteed individual outcome; treatment choice requires clinical discussion.

A tablet is not automatically less effective than an injection. In ATTAIN-1, the highest studied Foundayo dose averaged 11.2% weight reduction at 72 weeks in an analysis including people who stopped treatment. Some injections produced larger averages in separate trials, but these were not head-to-head comparisons and cannot establish a direct ranking.

What did ATTAIN-1 measure?

ATTAIN-1 was a phase 3 trial in adults with obesity or overweight and weight-related complications, without diabetes. Participants received orforglipron or placebo alongside lifestyle intervention. At week 72, the mean weight change in the highest-dose group was −11.2% under the treatment-regimen estimand, compared with −2.1% for placebo. This estimate reflects the treatment strategy assigned in the trial and accounts for outcomes after treatment discontinuation or use of additional therapies according to prespecified rules. It is not the same as the efficacy estimand, which asks a more hypothetical question about outcomes if participants had remained on assigned treatment without certain intercurrent events. The two estimates answer different questions; do not swap them or present one as the other.

What does an average mean?

A trial average is not an individual forecast. People vary in response, tolerability and whether they can continue treatment. The result also applies to the trial’s participants, duration and study conditions; it does not guarantee a particular outcome in routine care.

Can we compare it with injections?

Some injectable obesity medicines have reported larger average reductions in their own clinical trials. But trials can differ in populations, duration, dose, lifestyle support, analysis methods and handling of missing data. Comparing headline percentages across separate trials cannot establish that one treatment is more effective than another for an individual. A reliable ranking requires a suitable head-to-head trial, not a cross-study comparison.

Does the route determine the result?

The route—tablet or injection—is only one part of choosing treatment. Licensed indication, medical history, other medicines, possible adverse effects, practical preferences and access all matter. Orforglipron is an oral small molecule; it is not an injection in tablet form, and convenience does not equal superior results. Conversely, an injection is not necessarily more effective simply because it is injected.

Choosing and changing treatment safely

Discuss options with a qualified prescriber rather than choosing on one percentage. Do not stop an injection or start Foundayo without an agreed plan: medicines in this class can affect digestion, and switching may require attention to side effects, timing and other treatments. If pregnancy is possible, planned or confirmed, seek clinical advice before treatment; these medicines are not intended as weight-loss treatment during pregnancy. The UK authorisation is prescription-only and subject to ongoing safety monitoring.

Using trial results realistically

The percentage describes change in group-average body weight from baseline, not the proportion of people who lose exactly that amount. It is also a mean: some participants lost more, some less, and some may not have achieved clinically meaningful change. Trial duration matters because results at one time point do not describe what happens after that period or after treatment stops. Ongoing care and follow-up are important with any chronic weight-management strategy. Ask how the study population and endpoint relate to your situation, rather than treating the headline figure as a target or expected result. Bring any uncertainties to a qualified clinician or pharmacist, who can check the current UK product information and your individual circumstances. Online summaries are useful starting points, not a substitute for that review.